News

TIDES Europe: Oligonucleotide & Peptide Therapeutics in AMSTERDAM

Dr Guillaume JACQUOT will present "Targeted Drug Delivery to the CNS and Peripheral Tissues Using the VECTrans® Innovative Technology" during the TIDES Europe, 12-15 November 2019.


Meet VECT-HORUS at BIO Europe HAMBURG

VECT-HORUS will attend BIO Europe from November 11–13, 2019
If you are interested to meet, please use the B2B Partnering system.


Festival of Biologics 2019 in BASEL

Meet with Pascaline LECORCHE during the Festival of Biologics 2019, 15 – 17 October 2019 _ Basel Switzerland and discuss on « Design of peptide-based vectors for targeted delivery ».


VECT-HORUS will be attending the EANM’19 Congress in BARCELONA

Cedric MALICET PhD, Oncology Project Manager and Elodie DORMES, Business Development Manager will attend EANM from 12-16 October, 2019 in Barcelona to discuss Peptide Receptor Radionuclide Therapy strategy and partnered Vect-Horus’ (...)


Meet VECT-HORUS at BIO Japan

Dr Jamal TEMSAMANI, Drug Development and Corporate Director will attend BIO Japan from October 9–11, 2019
If you are interested to meet, please use the B2B Partnering system.


Relocation of the company to support its development

Relocation of Vect-Horus in medical faculty of the La Timone campus to maintain strong collaborative working environment with its historical partners and support its development.


VECT-HORUS announces Collaboration and Option Agreement with ASTELLAS Pharma

Vect-Horus announced today the signing of the Research Collaboration and Option Agreement (the “Agreement”) with Astellas Pharma Inc., a Japan based pharmaceutical company (“Astellas”). Vect-Horus will use its proprietary technology VECTrans® to (...)


VECT-HORUS will attend BIO International Convention in PHILADELPHIA

VECT-HORUS will attend BIO US in Philadelphia | June 3-6, 2019.
If you are interested to meet, please use the B2B Partnering system.


AD/PD 2019​ International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders in LISBON

Marion DAVID and Romy COHEN will present the “Development of vectors that cross the blood brain barrier to enhance CNS drug delivery in neurodegenerative diseases” in session A: β-Amyloid Diseases poster (...)


VECT-HORUS enters into Collaboration and License Agreement with ONO Pharmaceutical Co., Ltd.

Vect-Horus S.A.S. announced today the signing of a collaboration and license agreement with Ono Pharmaceutical Co., Ltd., focused on the development of novel molecules targeting neurodegenerative diseases


Meet VECT-HORUS at BIO Spring VIENNA

VECT-HORUS will attend BIO Europe from March 25–26, 2019
If you are interested to meet, please use the B2B Partnering system.
https://ebdgroup.knect365.com/bioeu...


Nanomedicine for treating cancer and brain diseases symposium in MARSEILLE

In the context of the Euronanomed projects for Action on Nanomedicine under Horizon 2020, a Symposium will be held at the Luminy campus in Marseille on March 8, 2019. Dr. Khrestchatisky will give a talk titled "Molecular vectors for drug (...)


VECT-HORUS and RadioMedix announce the signing of a LOI to co-develop a Vect-Horus’ radio-theranostic agent for Glioblastoma

Marseille, France- Houston - March 5, 2019 - Vect-Horus and RadioMedix announced today the signing of a Letter of Intent (LOI) to establish an agreement for the co-development of a Vect-Horus theranostic agent for the diagnostic and radiotherapy (...)


Signature of a Research Common Lab with the Institute for NeuroPhysiopathology (UMR7051 CNRS-AMU)

Since its incorporation in 2005 VECT-HORUS is a leading partner of the French academic institutions CNRS and Aix-Marseille University. Indeed, the company as a spin-off of the NICN (UMR7259 CNRS-AMU) now Institute for NeuroPhysiopathology INP (...)


VECT-HORUS announces agreement with Johnson&Johnson Innovation

Vect-Horus announced today the signing of a research collaboration agreement with Janssen Pharmaceuticals, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson.


Meet VECT-HORUS at BIO Europe COPENHAGEN

VECT-HORUS will attend BIO Europe from 5–7 November 2018.
If you are interested to meet, please use the B2B Partnering system.


VECT-HORUS will be attending the EANM’18 Congress in DÜSSELDORF

VECT-HORUS will present a poster on its proprietary technology platform, VECTrans®, for the targeting and delivery of imaging or therapeutic agents to tumors.
Please come and meet Cedric MALICET PhD, Oncology Project (...)


VECT-HORUS Raises 3.5M€ to Accelerate its Development Programs

VECT-HORUS, a biotechnology company that designs and develops vectors facilitating targeting of therapeutic molecules and imaging agents, announces completion of a new fund-raising round for 3.5 million euros, following a previous round of 2.5 (...)


BIO International Convention in BOSTON, MA

The BIO International Convention (BIO) attracts 16,000+ biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships.
VECT-HORUS’ business model is to make its (...)


ECMED EU-GliaPhD international conference in MALTA

Michel Khrestchatisky and Grigorios Kyriatzis (Early Stage Researcher, ESR), both members of the ITN Marie Curie project ECMED will participate in the ECMED EU-GliaPhD international conference organized in Malta, April 29 to May 2, 2018. Michel (...)


AAT-AD/PD Focus Meeting, TORINO Italy

Meet Marion DAVID Vect-Horus’ Vector Discovery platform Manager during the AAT-AD/PD Focus Meeting.
This Alzheimer’s disease conference and Parkinson’s disease conference will present all the latest breakthroughs in treatment, translational (...)


Meet VECT-HORUS at BIO Spring AMSTERDAM

VECT-HORUS will attend BIO Spring from 12-14 March 2018.
If you are interested to meet, please use the B2B Partnering system or send an email to Elodie DORMES, Business Development Manager at elodie.dormes(at)vect-horus(dot)com (...)


VECT-HORUS demonstrates the high versatility of its peptide-vectors library for a targeted delivery of small molecules and protein cargos

Identification and characterization of highly versatile peptide-vectors that bind non-competitively to the low-density lipoprotein receptor for in vivo targeting and delivery of small molecules and protein cargos.
Marion David, Pascaline (...)


Selected for a 5’ Pitch at the 2nd edition of the TOULOUSE ONCO WEEK

Cédric MALICET, PhD Oncology Project Manager, will present VECT-HORUS’ proprietary technology platform, VECTrans®, that facilitates the targeted delivery of imaging or therapeutic agents to tumors using receptor mediated transport. (...)


VECT-HORUS will be attending the J.P. Morgan 36th Annual Healthcare Conference

January 8-11, 2018 – San Francisco, CA, USA
If you would like to arrange a one-on-one meeting with Vect-Horus’ team during the conference, please contact Jamal TEMSAMANI, Director of Drug Development & Corporate at (...)


Gerhard Levy Distinguished Lectureship in Pharmaceutical Sciences for Prof. Scherrmann, chairman of VECT-HORUS’ Scientific Advisory Board

University at Buffalo, The State University of New York distinguished Professor Emeritus of Pharmaceutical Sciences Gerhard Levy was a pioneer and leading contributor in the areas of pharmacokinetics and clinical pharmacokinetics.
The Gerhard (...)


Meet VECT-HORUS at BIO Europe BERLIN

6-8/11/2017
Berlin, Germany
https://ebdgroup.knect365.com/bioeurope/


VECT-HORUS confirmed to attend BioPharm America 2017

26-27/09/2017
Boston USA
ebdgroup.knect365.com/biopharm-america/


VECT-HORUS announces the expansion of its Scientific Advisory Board

VECT-HORUS is a French biotechnology company that designs and develops peptide-vectors to facilitate the delivery of drugs or imaging agents into the brain and other organs, and in particular in tumours. VECT-HORUS announces the expansion of its (...)


Participation au BIOREZO™ VECTORISATION : DE L’IMAGERIE À LA THÉRAPEUTIQUE

Participation au BIOREZO™ VECTORISATION : DE L’IMAGERIE À LA THÉRAPEUTIQUE


VECT-HORUS at PIERRE FABRE DAYONE OPEN INNOVATION DAY

Vect-Horus selected for an elevator pitch during DAYONE 2017: an open innovation day dedicated to pharmaceutical innovation. The one day conference aim is to identify, bring out, and develop innovative projects by biopharmaceutical companies, (...)


Selected for an Elevator Pitch at the 3rd edition of MEET2WIN

Vect-Horus will participate to the MEET2WIN a French Business Convention entirely dedicated to open innovation, collaborative research and technology transfer.
https://www.b2match.eu/meet2win2017/participants/176


CNS Barrier Congress

22-23 March 2017 // Holiday Inn London Kensington Hotel


VECT-HORUS raises 2.5 M€ to finance its development projects in the “targeted therapy” field

Marseille, 22 Mars 2017 - The French biotechnology start up VECT-HORUS, a European leader in the design of vectors that facilitate the delivery of drugs into the brain and other organs, announces completion of a new fund raising round for 2.5 (...)


Meet VECT-HORUS at BIO Spring BARCELONA

March 20-22 // Barcelona, SPAIN


VECT-HORUS validates the potential of its peptide vectors to transport proteins or antibodies, across the blood-brain barrier via receptor mediated transport

(Molino et al., 2017, The FASEB Journal)
www.fasebj.org/content/early/2017/01/19/fj.201600827R.abstract


Meet VECT-HORUS at BIO Europe COLOGNE

November 7-9 // Köln, GERMANY


RIB 2016 PARIS – Neurological Disorders

Rendez-vous le 2 novembre 2016, 9h-18h au HUB Bpifrance, 8 Bd Haussmann, 75009 Paris


VECT-HORUS receives the Frost & Sullivan 2016 Leadership award

Press release
Communiqué de presse
French biotechnology startup VECT-HORUS, a European leader in the design of vectors that facilitate the delivery of drugs into the brain and other organs, receives the Frost & Sullivan 2016 Leadership award (...)


VECT-HORUS rejoint la communauté Bpifrance Excellence

L’entrée de la société de « CNS Drug Delivery » dans le cercle très fermé des membres de Bpifrance Excellence récompense l’innovation apportée par sa plateforme VECTrans®


Two new patents protecting VECTrans® technology issued in several major countries

Press release Communiqué de presse
VECT-HORUS, a biotechnology company that designs and develops peptide vectors for addressing drugs or imaging agents to the brain and other organs, announces the strengthening of its patent portfolio with the (...)


Boulder Peptide Symposium

VECT-HORUS to Present at Boulder Peptide Symposium 2015


Biopharm America 2015

VECT-HORUS will be present at Biopharm America 2015.


11th International Conference on Cerebral Vascular Biology

VECT-HORUS is sponsoring the 11th International Conference on Cerebral Vascular Biology (CVB 2015).


VECT-HORUS announces the signing of a scientific collaboration agreement with SERVIER

The two companies intend to enter in a collaboration agreement to develop new therapeutic molecules in the field of central nervous system (CNS) diseases
VECT-HORUS, a biotechnology company that designs and develops peptide vectors that (...)


Neurotensin, vectorised by VECT-HORUS, is the first drug-candidate in neuroprotective hypothermia

VECT-HORUS starts the regulatory preclinical development of VH-N439, positioned as a first-in-class neuroprotective agent in brain ischemia Neurotensin is a neuropeptide with global hypothermic potential when administered directly into the (...)


Meet VECT-HORUS at BIO-Europe Spring® 2015

Meet VECT-HORUSat BIO-Europe Spring® 2015, Paris, France
March 9-11, 2015


VECT-HORUS announces the signing of a scientific collaboration agreement with SANOFI in the field of neurodegenerative diseases

The goal of this collaboration is to use VECT-HORUS’ proprietary technology to transport therapeutic antibodies into the brain for the treatment of a neurodegenerative disease.


Meet VECT-HORUS at the 36th PAMM-EORTC Winter meeting

Pharmacology and Molecular Mechanisms Group (PAMM) of the European Organisation for Research and Treatment of Cancer (EORTC).
Meet VECT-HORUS at the 36th PAMM-EORTC Winter meeting, Marseille, France
January 21-24, (...)


VECT-HORUS announces a new equity issue of 1.5 M€ to finance the preclinical development of its first vectorized product

VECT-HORUS announced today having raised € 1.5 million, from its historical shareholders, mostly professionals in the finance industry. In total, VECT-HORUS raised in 9 years more than € 11 million, of which € 5 million in grants and research tax (...)


VECT-HORUS is one of the CNRS 15 success stories

VECT-HORUS was recently identified by the CNRS as one of the 15 success stories in 1,000 companies created from CNRS laboratories.


VECT-HORUS appoints Dr Jamal Temsamani as Director of Drug Development & Corporate

VECT-HORUS announced today the appointment of Dr. Jamal Temsamani as Director in charge of Drug Development & Corporate. He will lead the Company’s drug development programs from discovery to early clinical and will be in charge of industrial (...)


VECT-HORUS, AAA form scientific collaboration to open new avenues in treatment of brain diseases

The partnership will develop new molecules for the treatment of brain diseases
Vect-Horus, a French company specialized in the development of vector molecules for the central nervous system, announces today it has signed a scientific (...)


VECT-HORUS is a partner laureate of the ANR RPIB Call 2013 for proposals

VECT-HORUS is a partner laureate of the Agence Nationale de la Recherche (ANR) RPIB Call 2013 for proposals and will be involved in the VEC2Brain project involving 3 academic laboratories. The project will be coordinated by Dr Michel (...)


VECT-HORUS successfully completes the VECtoBrain project

Ths project was supported from 2009 to 2013 by the Agence Nationale de la Recherche (ANR) BiotecS Call 2009.
The project was coordinated by VECT-HORUS (Dr. Guillaume Jacquot) and involved the UMR7259 laboratory (CNRS and Aix-Marseille (...)


Two research groups specialized in CNS drug delivery and in the development of therapeutic strategies for glioblastoma give in vivo POC on one of the peptide vectors described by VECT-HORUS

Two groups of the Institute of Hematology, Huazhong University in Wuhan and the Key Laboratory of Smart Drug Delivery, Fudan University in Shanghai, well known and specialized in CNS drug delivery and in the development of therapeutic strategies (...)


Fifth round of funding

VECT-HORUS has completed a fifth round of venture capital funding from private shareholders.


VECT-HORUS and its academic partners describe the chemical optimisation of one of its lead peptides (Malcor et al., 2012, J Med Chem)

and publish a review article on CNS drug delivery (Vlieghe and Khrestchatisky, 2012, Med Res Rev).


VECT-HORUS is a partner laureate of the ANR MALZ 2011 call for proposals

VECT-HORUS is a partner laureate of the Agence Nationale de la Recherche (ANR) MALZ 2011 call for proposals and will be involved in the PREVENTAD project coordinated by the UMR7259 laboratory (Coordinator, Dr. Michel Khrestchatisky).
This (...)


Fourth round of financing

VECT-HORUS has completed a fourth round of venture capital funding from private shareholders.


VECT-HORUS is a partner laureate of the ANR MALZ 2010 call for proposals

VECT-HORUS is a partner laureate of the Agence Nationale de la Recherche (ANR) MALZ 2010 call for proposals and will be involved in the ADHOC project coordinated by the UMR7259 laboratory (Coordinator, Pr. François Féron).
This project received (...)